4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round
News & Library
Walter Global Asset Management, in partnership with Bonnefield Financial’s management team, acquires Canadian farmland asset management leader.
4BIO Capital’s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery.
Appointment of Professor Akiko Iwasaki to Scientific Advisory Board.
4BIO Capital announces its investment in SparingVision, a genomic medicine company focused on ocular diseases.
4BIO Capital announces appointment of Professor Kenya Honda to Scientific Advisory Board
4BIO Capital appoints Brian P. McVeigh, a seasoned pharma and biotech industry veteran, as Venture Partner to strengthen 4BIO Capital’s US operations.
4BIO Capital announces strategic investment from Japanese pharmaceutical company Kyowa Kirin. 8 June 2020
4BIO Capital portfolio company ADC Therapeutics SA closes an upsized IPO of over $267.6 million 20 May 2020
Discussion on background, progress, and impact of Covid19.
Media Coverage of the Ventures II Launch
4BIO Capital raises $50 million in first close of new advanced therapies fund. 4BIO Ventures II fund solely focused on advanced therapies.
Redpin Therapeutics secures initial closing of $15.5 million in Series A financing. 4BIO Capital and Arkin Bio Ventures lead first close joined by Takeda Ventures and existing investors.